AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed advanced solid tumors or lymphoma
• Must have measurable disease outside a previously irradiated field OR regrowth of tumor within a previously irradiated field
• Must be a candidate for gemcitabine hydrochloride treatment, in the opinion of the investigator
• No untreated or symptomatic brain metastases
• No tumors with direct bowel invasion
• No other hematological malignancies
• No non-small cell lung cancer of squamous cell histology or large central tumor (lesions ≥ 3 cm and located adjacent to or within the hilum or mediastinum)
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Not pregnant
• No nursing during and for 6 months after completion of study treatment
• Fertile patients must use effective contraception during and for 6 months after completion of study treatment
• Negative pregnancy test
• Able to swallow oral medication
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 9 g/dL
• Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 40 mL/min
• Albumin-adjusted calcium ≥ 8 mg/dL
• Urine protein \< 30 mg/dL by urinalysis or \< 1+ by dipstick OR \< 500 mg by 24-hour urine collection
• AST or ALT ≤ 2.5 times upper limit of normal (ULN) (5.0 times ULN in the presence of liver metastasis or primary hepatic neoplasm)
• Bilirubin ≤ 2 times ULN
• PT ≤ 2.0
• INR or PTT ≤ 1.5 times ULN
• Systolic blood pressure (BP) ≤ 145 mm Hg and diastolic BP ≤ 85 mm Hg (stable antihypertensive medication allowed)
• No myocardial infraction within the past year
• No arterial thrombosis or deep vein thrombosis within the past year
• No unstable angina
• No congestive heart failure
• No New York Heart Association class III-IV cardiac disease
• No other unstable or uncontrolled disease or condition relating to or impacting cardiac function
• No HIV positivity
• No other condition that would preclude study participation, compliance, or follow-up assessments
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• No prior enrollment into this study
• At least 1 month since prior investigational device or drug trial
• At least 1 month since prior major surgical procedure
• At least 3 weeks since prior systemic chemotherapy
• At least 2 weeks since prior radiotherapy
• At least 2 weeks since prior rifampin or phenobarbital
• At least 1 week since prior treatment with any of the following:
• * Ketoconazole
• * Itraconazole
• * Clarithromycin
• * Erythromycin
• * Cyclosporine or tacrolimus
• * Nefazodone
• * Herbal medications containing Hypericum perforatum (St. John's wort)
• At least 1 week since prior and no concurrent warfarin
• * Concurrent prophylactic anticoagulation therapy (e.g., low-dose warfarin \[≤ 2 mg/day\] or low molecular weight heparin) for venous or arterial access devices allowed
• No prior or concurrent kinase insert domain-receptor inhibitors
• No concurrent chemotherapy, radiotherapy, hormone-directed cancer therapy, or tumor-directed antibody therapy
• * Gonadotropin releasing-hormone agonist therapy allowed
• No concurrent interferon
• No concurrent grapefruit juice or whole grapefruit
• No other concurrent standard or investigational drugs or antitumor treatment, including c-kit, platelet-derived growth factor, vascular endothelial growth factor, or epidermal growth factor inhibitors
• No elective surgery during or for 2 weeks after completion of the last dose of AMG 706